News

Signum Biosciences has been awarded a $1.6m Small Business Innovation Research (SBIR) phase II grant by the National Institute of Allergy and Infection Diseases (NIAID), to continue the

The FDA has approved GenSpera’s Investigational New Drug (IND) application to begin a phase I study with its target activated pro-drug, G-202, for the treatment of cancer. G-202

New data from a study conduct by Eli Lilly showed that patients with chronic low back pain on Cymbalta (duloxetine HCl) has maintained reductions in pain for 41

Delcath Systems has reported that the Data and Safety Monitoring Board (DSMB) has reviewed clinical data on 77 patients enrolled in its pivotal phase III clinical trial. DSMB

Germany-based Merck has reported the results of the complete 40-week IMPROVE (Investigating MRI Parameters with Rebif imprOVEd formulation) study. Reportedly, the data showed a 69% reduction in the

Sanofi-aventis and Regeneron Pharmaceuticals have discontinued the phase 3 trial that evaluated aflibercept (VEGF Trap) plus gemcitabine versus placebo plus gemcitabine, for the first-line treatment of metastatic pancreatic

Biocon and Amylin Pharmaceuticals (Amylin) have entered into an exclusive agreement to jointly develop, commercialise and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Reportedly,

Levi & Korsinsky, a law firm has filed lawsuit in Delaware Chancery court challenging the proposed acquisition of Sepracor. The complaint arises out of the announcement by Sepracor

AgraQuest and Alpharma Animal Health have agreed to terms for a supply agreement in which AgraQuest will supply their strain of Bacillus subtilis. This input will be used